IGC Pharma, Inc. SEC filings IGC
IGC Pharma, Inc. has 817 filings in SEC EDGAR's recent list, going back to May 13, 2005. Its latest annual report, Form 10-KT, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jul 14, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 22, 2026 | — |
| DEF 14A | Proxy statement | Oct 22, 2026 | Dec 2, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 14, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 8, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Apr 20, 2026 | Apr 14, 2026 |
| 8-K |
Current report
Other events
|
Mar 30, 2026 | Mar 30, 2026 |
| 10-KT | Transition report | Mar 18, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Mar 12, 2026 | Mar 6, 2026 |
| 8-K |
Current report
Material agreement
|
Jan 6, 2026 | Jan 5, 2026 |
| 424B5 | Prospectus supplement | Jan 6, 2026 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jan 2, 2026 | Dec 30, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 15, 2025 | Dec 12, 2025 |
| EFFECT | Filing | Dec 5, 2025 | — |
| CORRESP | Letter to the SEC | Dec 4, 2025 | — |
| S-3/A | Form s-3/a | Dec 3, 2025 | — |
| S-3 | Shelf registration | Nov 17, 2025 | — |
| S-8 | Employee stock plan registration | Nov 14, 2025 | — |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Acquisition or sale of assets
|
Nov 14, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 14, 2025 | Oct 10, 2025 |
| 8-K |
Current report
Material agreement
|
Oct 1, 2025 | Oct 1, 2025 |
| 424B5 | Prospectus supplement | Sep 19, 2025 | — |
| DEFA14A | Additional proxy material | Aug 19, 2025 | — |
| DEF 14A | Proxy statement | Aug 18, 2025 | Oct 10, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| PRE 14A | Preliminary proxy statement | Aug 4, 2025 | Oct 10, 2025 |
| EFFECT | Filing | Jul 28, 2025 | — |
| CORRESP | Letter to the SEC | Jul 24, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2025 | — |
| S-3 | Shelf registration | Jul 18, 2025 | — |
| 10-K | Annual report | Jun 27, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Other events
|
Jun 17, 2025 | Jun 17, 2025 |
| 10-Q | Quarterly report | Feb 14, 2025 | Dec 31, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 27, 2024 | Sep 25, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Aug 27, 2024 | Aug 23, 2024 |
| 10-Q | Quarterly report | Aug 7, 2024 | Jun 30, 2024 |
| UPLOAD | Letter from the SEC | Aug 7, 2024 | — |
| 8-K |
Current report
Material agreement, New debt
|
Aug 2, 2024 | Jul 29, 2024 |
| DEFA14A | Additional proxy material | Jul 9, 2024 | — |
| DEF 14A | Proxy statement | Jul 8, 2024 | Aug 23, 2024 |
| 10-K | Annual report | Jun 24, 2024 | Mar 31, 2024 |
| EFFECT | Filing | May 2, 2024 | — |
| CORRESP | Letter to the SEC | Apr 30, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 19, 2024 | — |
| S-3 | Shelf registration | Apr 18, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 5, 2024 | Mar 20, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Mar 28, 2024 | Mar 22, 2024 |
| 8-K |
Current report
Material agreement
|
Mar 22, 2024 | Mar 19, 2024 |
| 424B5 | Prospectus supplement | Mar 22, 2024 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 13, 2024 | Mar 12, 2024 |
| 10-Q | Quarterly report | Feb 14, 2024 | Dec 31, 2023 |
| 424B5 | Prospectus supplement | Jan 31, 2024 | — |
| EFFECT | Filing | Jan 8, 2024 | — |
| CORRESP | Letter to the SEC | Jan 4, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 4, 2024 | — |
| S-3 | Shelf registration | Dec 29, 2023 | — |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Material agreement
|
Oct 27, 2023 | Oct 27, 2023 |
| 424B5 | Prospectus supplement | Oct 27, 2023 | — |
| EFFECT | Filing | Oct 5, 2023 | — |
| CORRESP | Letter to the SEC | Oct 4, 2023 | — |
| S-8 | Employee stock plan registration | Oct 4, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2023 | — |
| S-3 | Shelf registration | Sep 29, 2023 | — |
| 8-K |
Current report
Shareholder vote results, Other events
|
Aug 21, 2023 | Aug 18, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| DEF 14A | Proxy statement | Jul 26, 2023 | Aug 18, 2023 |
| 10-K | Annual report | Jul 7, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 7, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 7, 2023 | Jun 30, 2023 |
| NT 10-K | Form nt 10-k | Jun 30, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Officer or director change
|
May 8, 2023 | May 5, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Mar 21, 2023 | Mar 20, 2023 |
| 10-Q | Quarterly report | Feb 14, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 29, 2022 | Dec 24, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 20, 2022 | Dec 19, 2022 |
| 10-Q | Quarterly report | Nov 1, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Sep 9, 2022 | Sep 9, 2022 |
| 10-Q | Quarterly report | Aug 5, 2022 | Jun 30, 2022 |
| DEF 14A | Proxy statement | Jul 25, 2022 | Sep 9, 2022 |
| 10-K | Annual report | Jun 23, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Other events
|
Jun 9, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Material agreement
|
May 12, 2022 | May 10, 2022 |
| 8-K |
Current report
Other events
|
Apr 18, 2022 | Apr 13, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 23, 2022 | Mar 23, 2022 |
| 10-Q | Quarterly report | Feb 10, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 18, 2022 | Jan 18, 2022 |
| S-8 | Employee stock plan registration | Dec 23, 2021 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 2, 2021 | Dec 1, 2021 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Nov 19, 2021 | Nov 18, 2021 |
| 10-Q | Quarterly report | Oct 29, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Oct 15, 2021 | Oct 15, 2021 |
| DEF 14A | Proxy statement | Sep 15, 2021 | Oct 15, 2021 |
| 10-Q | Quarterly report | Aug 11, 2021 | Jun 30, 2021 |
| 10-K | Annual report | Jun 14, 2021 | Mar 31, 2021 |
| 10-Q | Quarterly report | Feb 16, 2021 | Dec 31, 2020 |
| EFFECT | Filing | Jan 29, 2021 | — |
| POS AM | Form pos am | Jan 22, 2021 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Jan 14, 2021 | Jan 11, 2021 |
| 424B5 | Prospectus supplement | Jan 13, 2021 | — |
| 8-K |
Current report
Material agreement
|
Jan 13, 2021 | Jan 13, 2021 |
| EFFECT | Filing | Jan 4, 2021 | — |
| CORRESP | Letter to the SEC | Dec 31, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 31, 2020 | — |
| S-3 | Shelf registration | Dec 23, 2020 | — |
| DEFA14A | Additional proxy material | Dec 22, 2020 | — |
| 8-K |
Current report
Other events
|
Dec 22, 2020 | Dec 21, 2020 |
| DEF 14A | Proxy statement | Dec 8, 2020 | Jan 11, 2021 |
| 10-Q | Quarterly report | Nov 20, 2020 | Sep 30, 2020 |
| NT 10-Q | Form nt 10-q | Nov 13, 2020 | Sep 30, 2020 |
| 8-K |
Current report
Other events
|
Aug 20, 2020 | Aug 19, 2020 |
| 10-Q | Quarterly report | Aug 19, 2020 | Jun 30, 2020 |
| NT 10-Q | Form nt 10-q | Aug 14, 2020 | Jun 30, 2020 |
| 8-K |
Current report
Other events
|
Aug 11, 2020 | Jul 30, 2020 |
| 8-K |
Current report
Other events
|
Jul 20, 2020 | Jul 8, 2020 |
| 10-K | Annual report | Jul 13, 2020 | Mar 31, 2020 |
| NT 10-K | Form nt 10-k | Jun 29, 2020 | Mar 31, 2020 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale
|
May 13, 2020 | May 11, 2020 |
| 8-K |
Current report
Other events
|
May 8, 2020 | May 7, 2020 |
| 8-K |
Current report
Other events
|
Mar 27, 2020 | Mar 26, 2020 |
| 8-K |
Current report
Other events
|
Mar 16, 2020 | Mar 13, 2020 |
| S-8 | Employee stock plan registration | Feb 25, 2020 | — |
| 10-Q | Quarterly report | Feb 10, 2020 | Dec 31, 2019 |
| 8-K |
Current report
Shareholder vote results
|
Jan 9, 2020 | Jan 7, 2020 |
| DEF 14A | Proxy statement | Dec 13, 2019 | Jan 7, 2020 |
| 10-Q | Quarterly report | Nov 6, 2019 | Sep 30, 2019 |
| 10-Q | Quarterly report | Aug 9, 2019 | Jun 30, 2019 |
| 10-K | Annual report | Jun 14, 2019 | Mar 31, 2019 |
| 8-K |
Current report
Other events
|
Mar 27, 2019 | Mar 26, 2019 |
| 8-K |
Current report
Other events
|
Feb 26, 2019 | Feb 26, 2019 |
| 8-K |
Current report
Other events
|
Feb 22, 2019 | Feb 20, 2019 |
| 8-K |
Current report
Change to shareholder rights
|
Feb 19, 2019 | Feb 19, 2019 |
| 10-Q | Quarterly report | Feb 12, 2019 | Dec 31, 2018 |
| 8-K |
Current report
Listing notice, Other events
|
Nov 13, 2018 | Nov 6, 2018 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Nov 2, 2018 | Oct 29, 2018 |
| 10-Q | Quarterly report | Oct 16, 2018 | Sep 30, 2018 |
| S-3 | Shelf registration | Oct 15, 2018 | — |
| 8-K |
Current report
Other events
|
Oct 10, 2018 | Oct 4, 2018 |
| 424B5 | Prospectus supplement | Oct 2, 2018 | — |
| 8-K |
Current report
Other events
|
Oct 1, 2018 | Oct 1, 2018 |
| 8-K |
Current report
Material agreement
|
Oct 1, 2018 | Oct 1, 2018 |
| 424B5 | Prospectus supplement | Oct 1, 2018 | — |
| 8-K |
Current report
Material agreement
|
Sep 24, 2018 | Sep 22, 2018 |
| 424B5 | Prospectus supplement | Sep 24, 2018 | — |
| 424B5 | Prospectus supplement | Sep 24, 2018 | — |
| 8-K |
Current report
Material agreement
|
Sep 12, 2018 | Sep 12, 2018 |
| S-8 | Employee stock plan registration | Aug 21, 2018 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Aug 7, 2018 | Aug 6, 2018 |
| 10-Q | Quarterly report | Aug 3, 2018 | Jun 30, 2018 |
| DEF 14A | Proxy statement | Jul 6, 2018 | Aug 6, 2018 |
| 10-K | Annual report | Jun 21, 2018 | Mar 31, 2018 |
| 8-K |
Current report
Officer or director change
|
May 15, 2018 | May 9, 2018 |
| EFFECT | Filing | May 11, 2018 | — |
| CORRESP | Letter to the SEC | May 9, 2018 | — |
| S-3/A | Filing | May 9, 2018 | — |
| 8-K |
Current report
Other events
|
May 4, 2018 | Apr 30, 2018 |
| S-3/A | Filing | Apr 30, 2018 | — |
| 8-K |
Current report
Auditor change
|
Apr 12, 2018 | Apr 11, 2018 |
| S-3 | Shelf registration | Apr 2, 2018 | — |
| 8-K |
Current report
Auditor change
|
Mar 19, 2018 | Mar 16, 2018 |
| 8-K |
Current report
Other events
|
Mar 2, 2018 | Feb 28, 2018 |
| 10-Q | Quarterly report | Feb 20, 2018 | Dec 31, 2017 |
| NT 10-Q | Filing | Feb 14, 2018 | Dec 31, 2017 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jan 2, 2018 | Dec 29, 2017 |
| 8-K |
Current report
Material agreement
|
Dec 22, 2017 | Dec 20, 2017 |
| 424B5 | Prospectus supplement | Dec 22, 2017 | — |
| 424B5 | Prospectus supplement | Dec 22, 2017 | — |
| 8-K |
Current report
Other events
|
Dec 18, 2017 | Dec 15, 2017 |
| 8-K |
Current report
Material agreement
|
Nov 30, 2017 | Nov 29, 2017 |
| 424B5 | Prospectus supplement | Nov 30, 2017 | — |
| 8-K |
Current report
Other events
|
Nov 22, 2017 | Nov 22, 2017 |
| 10-Q | Quarterly report | Nov 17, 2017 | Sep 30, 2017 |
| NT 10-Q | Filing | Nov 13, 2017 | Sep 30, 2017 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Nov 13, 2017 | Nov 8, 2017 |
| 8-K |
Current report
Listing notice
|
Oct 12, 2017 | Oct 12, 2017 |
| DEF 14A | Proxy statement | Oct 10, 2017 | Nov 8, 2017 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2017 | Sep 27, 2017 |
| CORRESP | Letter to the SEC | Sep 15, 2017 | — |
| PRE 14A | Preliminary proxy statement | Sep 15, 2017 | Sep 15, 2017 |
| 10-Q | Quarterly report | Aug 18, 2017 | Jun 30, 2017 |
| NT 10-Q | Filing | Aug 14, 2017 | Jun 30, 2017 |
| 10-K | Annual report | Jul 14, 2017 | Mar 31, 2017 |
| NT 10-K | Filing | Jun 30, 2017 | Mar 31, 2017 |
| 8-K |
Current report
Other events
|
Jun 12, 2017 | Jun 12, 2017 |
| 8-K |
Current report
Other events
|
May 25, 2017 | May 25, 2017 |
| 8-K |
Current report
Other events
|
Apr 25, 2017 | Apr 25, 2017 |
| 8-K |
Current report
Listing notice
|
Apr 21, 2017 | Apr 20, 2017 |
| 8-K |
Current report
Acquisition or sale of assets
|
Apr 5, 2017 | Apr 3, 2017 |
| 8-K |
Current report
Listing notice
|
Apr 5, 2017 | Apr 3, 2017 |
| UPLOAD | Letter from the SEC | Apr 3, 2017 | — |
| CORRESP | Letter to the SEC | Mar 30, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2017 | — |
| CORRESP | Letter to the SEC | Mar 29, 2017 | — |
| CORRESP | Letter to the SEC | Mar 8, 2017 | — |
| PRE 14A | Preliminary proxy statement | Mar 8, 2017 | Mar 31, 2017 |
| 8-K/A | Amended current report | Feb 28, 2017 | Dec 30, 2016 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IGC (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- MD
- Headquarters
- Potomac, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1326205
- Former names
- India Globalization Capital, Inc. (until Mar 21, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.